Author

M. Bilenky

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Assay:DNA methylation· 1 Approach:statistical model· 1

Frequent Co-Authors

M. Hirst· 3 shared M. Moksa· 2 shared A. Carles· 1 shared A. Heravi-Moussavi· 1 shared A. Lorzadeh· 1 shared A. M. Joshua· 1 shared A. R. Hansen· 1 shared B. Bapat· 1 shared

Activity by Year

2020-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. Hirst

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Polycomb contraction differentially regulates terminal human hematopoietic differentiation programs

A. Lorzadeh, C. Hammond, D. Knapp, Q. Cao, F. Wang, A. Heravi-Moussavi, M. Wong, M. Bilenky, M. Moksa, Z. Sharafianardakani, P. Lavoie, C. Eaves, M. Hirst

The paper shows that H3K27me3 chromatin state changes are critical for terminal differentiation in human hematopoiesis, being retained in lymphoid cells but lost in monocytes and erythroblasts.

bioRxiv · Jun 4, 2020Cell Biology

Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment

M. R. Peter, M. Bilenky, R. Isserlin, G. D. Bader, S. Y. Shen, D. D. De Carvalho, A. R. Hansen, P. Hu, N. E. Fleshner, A. M. Joshua, M. Hirst, B. Bapat

This study examines methylation changes in cell-free DNA of mCRPC patients during androgen-targeting therapy, finding that persistent methylation changes correlate with longer time to clinical progression.

bioRxiv · Apr 8, 2020Cancer Biology

The pathognomonic FOXL2 C134W mutation alters DNA binding specificity

A. Carles, G. Trigo-Gonzalez, R. Cao, S.- W. G. Cheng, M. Moksa, M. Bilenky, G. B. Morin, D. G. Huntsman, M. Hirst

This study investigates the molecular effects of the FOXL2 C134W mutation in AGCT by analyzing DNA binding and transcriptome changes in engineered cell lines.

bioRxiv · Mar 20, 2020Cancer Biology